T hromboprophylaxis is the primary treatment focus in patients with atrial fibrillation (AF) due to the 5-fold increased risk of ischemic stroke compared with that in the general population.
The potential benefit of antithrombotic treatment in AF patients is based on the expected difference between the decreased risk of ischemic stroke and the increased risk of bleeding (1) . In addition to the increased risk of stroke, patients with AF are also at increased risk of developing coronary artery disease (CAD), including myocardial infarction (MI) (2) .
Atherothrombosis and AF often coexist and share similar pathogenic mechanisms (3) . The overlap of risk factors leading to the development of both atherothrombosis and AF adds to the complexity of determining the optimal antithrombotic treatment strategy for the primary prevention of both stroke and atherothrombotic events in AF patients. For the prevention of CAD, acetylsalicylic acid (ASA) therapy is standard of care, but in patients with AF, anticoagulation with vitamin K antagonists (VKA) has been shown to be more beneficial than ASA in preventing ischemic stroke (4) (5) (6) . Most of the previous studies of MI risk in patients with AF have investigated the risk of recurrent MI, whereas data for the effectiveness of ASA and VKA in primary prevention of MI is lacking (7, 8) . In this nationwide study, we investi-cohort of patients with AF and the risk of MI according to type of antithrombotic treatment regimen.
METHODS
DATA REGISTRIES. For all Danish residents, the health care system, both primary and secondary care, is tax-financed and free of charge, and drug pre- Table 1 shows all ICD and ATC codes used in this study) (12) . For ASA, the daily dosage was fixed, whereas for VKA, the estimated daily dosage could change. All definitions of exposure were based on prior prescriptions without conditions on future prescriptions. Therefore patients were considered exposed only if they received a prescription of antithrombotic therapy and were able to change therapy groups. Their exposure status was continually updated under the follow-up period. This method of change of dosage and exposure status during follow-up has previously been described (15) . Table 1 ) (14, 17, 18) . 
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INCIDENCE OF MI.
The overall annual rate of MI in our study is similar to that reported in other observational studies of AF patients, where the annual rates of MI ranged from 0.4% to 2.5% (20) . In a recent study by Soliman et al. (2) , the incidence rate of MI was 12 per 1,000 PY (95% CI: 9.6 to 14.9). That study showed that the risk of developing MI was almost twice as high for AF patients than for patients without AF. Higher incidence rates of MI have been found in patients with concomitant stable ischemic heart disease and in patients undergoing As INR was unknown in our study, we were not able to ascertain whether patients were in therapeutic range when the MI occurred. This may explain why we found dual-therapy to be associated with a greater risk of MI than VKA monotherapy. To further investigate the lack of effect of ASA-based therapy, we investigated whether it was dependent on the dosage of ASA. We found that ASA-based therapy had no beneficial effect, regardless of dose. This lack of efficacy of ASA may be that the underlying pathophysiology for MI in patients with AF may be less due to plaque rupture. The bleeding risk was significantly increased in the dual-therapy group compared to that in the VKA group, which is also supported by several studies (15, 18, 25) . 
